Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders. Here, we demonstrate that the transport of human antibodies across the BBB in mice can be enhanced by modulating their interactions with the neonatal Fc receptor (FcRn). When M252Y/S254T/T246E substitutions are introduced on the antibody Fc domain, immunohistochemical assays reveal widespread distribution of the engineered antibodies throughout the mouse brain. These engineered antibodies remain specific for their antigens and retain pharmacological activity. We propose that novel brain-targeted therapeutic antibodies can be engineered to differentially engage FcRn for receptor-mediated transcytosis across the BBB in order to improve neurological disease therapeutics in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
mAbs - 15(2023), 1 vom: 19. Jan., Seite 2229098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tien, Jason [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 07.07.2023 Date Revised 07.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/19420862.2023.2229098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358824745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358824745 | ||
| 003 | DE-627 | ||
| 005 | 20231226075552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19420862.2023.2229098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358824745 | ||
| 035 | |a (NLM)37381177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tien, Jason |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2023 | ||
| 500 | |a Date Revised 07.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders. Here, we demonstrate that the transport of human antibodies across the BBB in mice can be enhanced by modulating their interactions with the neonatal Fc receptor (FcRn). When M252Y/S254T/T246E substitutions are introduced on the antibody Fc domain, immunohistochemical assays reveal widespread distribution of the engineered antibodies throughout the mouse brain. These engineered antibodies remain specific for their antigens and retain pharmacological activity. We propose that novel brain-targeted therapeutic antibodies can be engineered to differentially engage FcRn for receptor-mediated transcytosis across the BBB in order to improve neurological disease therapeutics in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blood-brain barrier (BBB) | |
| 650 | 4 | |a Trojan horse | |
| 650 | 4 | |a central nervous system (CNS) | |
| 650 | 4 | |a immunoglobulin G (IgG) | |
| 650 | 4 | |a neonatal fc receptor (FcRn) | |
| 650 | 4 | |a transcytosis | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Leonoudakis, Dmitri |e verfasserin |4 aut | |
| 700 | 1 | |a Petrova, Ralitsa |e verfasserin |4 aut | |
| 700 | 1 | |a Trinh, Vivian |e verfasserin |4 aut | |
| 700 | 1 | |a Taura, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Debapriya |e verfasserin |4 aut | |
| 700 | 1 | |a Jo, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sho, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Yun, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Doan, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Jamin, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Hallak, Hussein |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Stratton, Jennifer R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mAbs |d 2009 |g 15(2023), 1 vom: 19. Jan., Seite 2229098 |w (DE-627)NLM194097110 |x 1942-0870 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:19 |g month:01 |g pages:2229098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/19420862.2023.2229098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 19 |c 01 |h 2229098 | ||